2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170545
    SARS-CoV-2 Mpro-IN-35 98%
    SARS-CoV-2 Mpro-IN-35 (compound 14) is a SARS-CoV-2 Mpro inhibitor. SARS-CoV-2 Mpro-IN-35 can be used for the research of SARS-CoV-2 virus.
    SARS-CoV-2 Mpro-IN-35
  • HY-170547
    DNA polymerase-IN-6 2701561-91-1 98%
    DNA polymerase-IN-6 (Compound 27) exhibits inhibitory activity against DNA polymerase, and inhibits HCMV, HSV-1, HSV-2 and EBV with EC50s of 0.33, 1.9, 0.76 and 0.066 µM, respectively.
    DNA polymerase-IN-6
  • HY-170567
    DNA gyrase/Topo IV-IN-1 98%
    DNA gyrase/Topo IV-IN-1 (Compound 27) is an inhibitor of DNA gyrase and topoisomerase IV, exhibiting antibacterial activity. For Escherichia coli and methicillin-resistant Staphylococcus aureus DNA gyrases, DNA gyrase/Topo IV-IN-1 has an IC50 of 11 and 17 nM respectively, and for topoisomerase IV of Escherichia coli and methicillin-resistant Staphylococcus aureus, the IC50 values are 83 and 21 nM respectively. DNA gyrase/Topo IV-IN-1 can be used for research in the field of anti-infection.
    DNA gyrase/Topo IV-IN-1
  • HY-170575
    Pks13-IN-1 98%
    Pks13-IN-1 (Compound 44) is an orally active inhibitor for Mycobacterium tuberculosis Polyketide synthase 13 (Pks13). Pks13-IN-1 inhibits M. tuberculosis strain H37Rv with a MIC of 0.07 μM. Pks13-IN-1 exhibits antibacterial efficacy in mouse model.
    Pks13-IN-1
  • HY-170599
    H117 99.27%
    H117 is a PROTAC target protein ligand that can be used to synthesize PROTAC HP211206 (HY-170598). H117 has competitive binding and inhibition ability on SARS-CoV-2 main protease (Mpro) with an IC50 of 151.3 nM.
    H117
  • HY-170600
    Boc-Ala(Me)-H117 98%
    Boc-Ala(Me)-H117 is the active control for the target protein ligand H117 (HY-170599) of PROTAC HP211206 (HY-170598).
    Boc-Ala(Me)-H117
  • HY-170608
    Urease-IN-18 98%
    Urease-IN-18 (compound 13a) is an uncompetitive urease inhibitor with an IC50 value of 1.6 μM. Urease helps maintain an alkaline environment favorable for the survival and proliferation of specific pathogens within the host.
    Urease-IN-18
  • HY-170616
    JH-FK-08 98%
    JH-FK-08 is an inhibitor for the serine/threonine-specific phosphatase calcineurin. JH-FK-08 exhibits antifungal activity that inhibits C. neoformans with MIC80 of 0.8 µg/mL. JH-FK-08 exhibits immunosuppressive activity and inhibits the IL-2 expression with an IC50 of 42.6 nM. JH-FK-08 exhibits anti-infectious activity in mouse models.
    JH-FK-08
  • HY-170646
    Influenza A virus-IN-15 98%
    Influenza A virus-IN-15 (Compound 9b), a quinoline derivative, is a broad-spectrum inhibitor of influenza A viruses with acceptable cytotoxicity (IC50: 0.88-6.33 μM). Influenza A virus-IN-15 can inhibit the transcription and replication of viral RNA and is used in research for its antiviral effects against influenza A viruses (IAV).
    Influenza A virus-IN-15
  • HY-170649
    RdRP-IN-9 1101848-34-3 98%
    RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC50 value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structural protein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) .
    RdRP-IN-9
  • HY-170650
    SMase-IN-1 33017-85-5 98%
    SMase-IN-1 (Compound 4) is a bacterial sphingomyelinase enzyme (SMase) inhibitor (IC50 value for B. cereus SMase is 6.43 µM). SMase-IN-1 also inhibits eqBuChE (59.50% inhibition rate at 50 µM concentration). SMase-IN-1 forms a complex with Cu2+ in biometal interactions. SMase-IN-1 reduces B. cereus-induced hemolysis on sheep erythrocytes.
    SMase-IN-1
  • HY-170688
    Antibacterial agent 119 98%
    Antibacterial agent 119 (Compound 21 g) is an antibacterial candidate against Methicillin (HY-121544)-resistant Staphylococcus aureus (MICs less than 1 μg/mL against tested strains). Antibacterial agent 119 induces ROS production. Antibacterial agent 119 also acts on the bacterial cell membrane to cause membrane breakage. Antibacterial agent 119 exhibits potent antibacterial activity with low cytotoxicity, rapid bactericidal ability, and good in vivo antibacterial activity.
    Antibacterial agent 119
  • HY-170760
    Antibacterial agent 258 3054254-13-3 98%
    Antibacterial agent 258 (Compound 11e) is an antibacterial agent, that destory the bacteria cell membrane, and inhibits various gram-positive bacteria (MIC for Staphylococcus aureus is 1-2 μg/mL). Antibacterial agent 258 exhibits low hemolytic activity and low cytotoxicity. Antibacterial agent 258 exhibits anti-infectious efficacy in mouse models.
    Antibacterial agent 258
  • HY-170777
    SLU-10906 3065121-94-7 98%
    SLU-10906 (Compound 63) is an orally active and potent Cryptosporidium inhibitor. SLU-10906 is active against the parasite in a cell-based infection model (EC50= 0.19 μM) and non-cytotoxic. SLU-10906 is promising for research of cryptosporidiosis.
    SLU-10906
  • HY-170780
    DSM1465 98%
    DSM1465 (Compound 82) is a potent, selective inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 value of 15 nM, inhibits P. falciparum 3D7 (Pf3D7) parasites with an EC50 value of 1.4 nM. DSM1465 shows potent in vivo activity in the humanized P. falciparum mouse model.
    DSM1465
  • HY-170782
    CZP-IN-1 98%
    CZP-IN-1 (compound SH-1) is an inhibitor targeting the pathogen Trypanosoma cruzi cruzipain (CZP) and does not inhibit cathepsin L (IC50=28 nM). CZP-IN-1 can be used for the research of Chagas disease.
    CZP-IN-1
  • HY-170783
    DXR-IN-4 98%
    DXR-IN-4 (Compound 12a) is the inhibitor for 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR). DXR-IN-4 inhibits DXR in Plasmodium falciparum Pf DXR, Escherichia coli Ec DXR, and Mycobacterium tuberculosis Mt DXR with IC50s of 18, 4.9 and 89 nM, respectively. DXR-IN-4 exhibits antimalarial activity that inhibits P. falciparum strains 3D7 and Dd2 with IC50 of 11 μM and 12 μM.
    DXR-IN-4
  • HY-170802
    Anti-MRSA agent 22 98%
    Anti-MRSA agent 22 (Compound 5a) is a potent antibacterial agent against MRSA with a MIC value of 6 µg/mL. Anti-MRSA agent 22 exhibits high binding affinity (−11.19) to FabI.
    Anti-MRSA agent 22
  • HY-170803
    KPC-IN-1 98%
    KPC-IN-1 (compound 1e) is an inhibitor of Klebsiella pneumoniae carbapenemase KPC-2 (IC50=8.3 nM). KPC is a β-lactamase expressed in Gram-negative bacteria that hydrolyzes carbapenems. KPC causes significant bacterial resistance to carbapenem antibiotics.
    KPC-IN-1
  • HY-170810
    E.coli Gyrase B-IN-1 98%
    E.coli Gyrase B-IN-1 (Compound 10g) is a E.coli Gyrase B inhibitor with antibacterial activities. E.coli Gyrase B-IN-1 has potent inhibitory activity against E. coli, with a MIC value of 0.12 mM. E.coli Gyrase B-IN-1 is promising for research of antimicrobial agents.
    E.coli Gyrase B-IN-1
Cat. No. Product Name / Synonyms Application Reactivity